ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca buys second Amgen site

by Lisa M. Jarvis
October 17, 2016 | APPEARED IN VOLUME 94, ISSUE 41

AstraZeneca has bought a second biologics site in Colorado from Amgen. The Longmont facility, reported by local media outlets to have been acquired for $64.5 million, will be used to support operations at the Boulder site that the company bought from Amgen in September 2015. The purchase of the Boulder plant doubled AstraZeneca’s U.S. manufacturing capacity for biologics, which occupy a growing proportion of the company’s drug pipeline. AstraZeneca says it will add staff in Longmont as its pipeline matures.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment